Study Name:
A Study of Lazertinib and Amivantamab in Participants with Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Targeted Disease(s):
Lung Cancer
Purpose of Study:
A Study of Lazertinib and Amivantamab in Participants with Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerStudy Dates:
August 5, 2022 - August 1, 2024
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Janssen Research & Development, LLC
Sponsors:
Janssen Research & Development, LLCContact:
Phone: 1-844-434-4210Email: Participate-In-This-Study@its.jnj.com
ClinicalTrails.gov Identifier:
NCT05388669
